What insurance does a medical device company need around 510(k) clearance?

FDA 510(k) clearance is the regulatory permission to market a Class II medical device based on substantial equivalence to a legally marketed predicate. Clearance itself does not trigger products liability — commercial sale does — but most companies place or scale their insurance program in the 60-90 days before clearance because the time from clearance to first commercial sale is often short and insurance underwriting takes weeks.

The structural program for a 510(k)-cleared device at commercial launch includes: products liability tower sized to expected revenue and device risk class, recall coverage as standalone, professional liability/E&O for any clinical or technical services scope, D&O scaled to investor expectations, and cyber for any connected-device data flow.

A 510(k)-cleared Class II device with expected first-year revenue under $10M typically needs $5M per-occurrence and $10M aggregate products liability as the entry tower. Class II implantables, neurostimulators, infusion pumps, or other higher-risk subcategories push the tower toward $10M per-occurrence and $25M aggregate even at modest revenue. The trigger for higher limits is not revenue alone but the severity profile of the device — devices implanted in the body, devices connected to patients during critical care, or devices delivering drugs all justify elevated tower sizing.

Carrier appetite for 510(k)-cleared Class II devices is narrower than for non-FDA-cleared products; specialty markets that write the class are familiar with the 510(k) process and the typical claims tail. Sourcing through a broker with documented Class II device experience produces materially better terms than placement through a generalist commercial broker.

The standard products liability policy includes an FDA-recall extension at a sublimit ($250K-$500K typical) that is structurally inadequate for a 510(k)-cleared device at commercial scale. A Class I or II recall of a Class II device routinely produces six- or seven-figure recall execution costs (notification, retrieval, replacement, destruction, lost gross profit) that the FDA-recall extension does not cover.

The structural fix is a standalone recall policy at $1M-$5M with explicit FDA Class I/II/III coverage. Premium is modest ($5,000-$20,000 annual) relative to the first-party exposure it covers.

Medical device companies that provide clinical services (implantation training, clinical follow-up programs, technical service contracts) or software components beyond the cleared device itself face professional liability exposure that products liability does not cover. A standalone Tech E&O or professional liability policy at $1M-$5M is structural for any device company with material services revenue.

SaMD components — software-as-a-medical-device — that meet FDA's Clinical Decision Support Final Guidance criteria also produce Tech E&O exposure layered on top of products liability. The two coverages run in parallel.

VC-backed medical device startups at 510(k) clearance often need to scale D&O coverage at the same time. Series A/B investor term sheets typically require $3M-$5M D&O; clearance triggers a step-up because the path-to-commercial timeline accelerates board-level decision-making and disclosure obligations.

For device companies on an M&A trajectory (often the exit pathway for clearable devices acquired by larger device strategics), transactional D&O for any equity-financing or M&A event is a separate consideration.

Underwriting for products liability on a 510(k)-cleared device typically takes 3-5 weeks from submission to bound coverage. Standard submission package includes: 510(k) summary or full submission, predicate device documentation, manufacturing site information (FDA registration, ISO 13485 certification, third-party audit results), clinical study data if available, prior loss history, and projected first-year revenue with channel mix.

The standard cadence: 90 days before expected clearance, broker engagement and submission preparation. 60 days before, market submissions and underwriting questions. 30 days before, bound coverage with effective date tied to first commercial sale. Companies that wait until after clearance to start the process face binder/effective-date pressure that limits negotiating leverage.